SUBSCRIBE
SUBSCRIBE

Phase 2

Policy
Biopharma Update on the Novel Coronavirus: April 7
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
April 7, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
April 6, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
Axon’s Tau Vaccine Shows Promise in Phase II Alzheimer’s Study
During a presentation at the AAT-AD/PD 2020 conference, Axon said AADvac1 showed a disease-modifying effect on Alzheimer’s disease.
April 3, 2020
 · 
2 min read
 · 
Alex Keown
BioCapital
Clinical Catch-Up: March 30 – April 3
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
April 3, 2020
 · 
14 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: April 3
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
April 3, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 2
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
April 2, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Drug Development
Sanofi and Regeneron Launch Second Kevzara Trial Against COVID-19
The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.
April 1, 2020
 · 
2 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: April 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 1, 2020.
April 1, 2020
 · 
8 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: March 31
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
March 31, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Drug Development
Reata Pharma Updates Business Operations and Clinical Trials in Light of COVID-19 Pandemic
“The adjustments we have made to our studies reflect our foremost concern for the safety and well-being of study participants, clinical investigators and their site staffs, our employees and communities as we face this challenging and unpredictable operating environment,” said Warren Huff, Reata’s chief executive officer and president.
March 31, 2020
 · 
2 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Press Releases
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 1, 2026
 · 
4 min read
Press Releases
Noema Pharma to Present Phase 2a Results for Cendifensine in Vasomotor Symptoms (Hot Flashes) Due to Menopause at the 2026 ACOG Annual Clinical & Scientific Meeting
May 1, 2026
 · 
2 min read
Press Releases
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
May 1, 2026
 · 
6 min read
Press Releases
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
May 1, 2026
 · 
5 min read
Press Releases
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
May 1, 2026
 · 
7 min read
Press Releases
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
April 30, 2026
 · 
6 min read
Press Releases
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
April 30, 2026
 · 
9 min read
Press Releases
Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554
April 30, 2026
 · 
3 min read
Press Releases
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
April 30, 2026
 · 
7 min read
Press Releases
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership
April 30, 2026
 · 
5 min read
Press Releases
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
April 30, 2026
 · 
7 min read
Press Releases
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
April 30, 2026
 · 
7 min read
Press Releases
Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis
April 30, 2026
 · 
4 min read
Press Releases
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
April 30, 2026
 · 
6 min read
Press Releases
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
April 30, 2026
 · 
13 min read
Press Releases
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer’s Disease
April 30, 2026
 · 
6 min read
Press Releases
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
April 30, 2026
 · 
5 min read
Press Releases
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
April 29, 2026
 · 
10 min read
Press Releases
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
April 29, 2026
 · 
9 min read
Press Releases
Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy’s Annual Meeting
April 29, 2026
 · 
2 min read
Load More